Why Corbus Pharmaceuticals Holdings, Inc.’s (CRBP) Stock Is Up 5.38%
As of Tuesday, August 04, Corbus Pharmaceuticals Holdings, Inc.’s CRBP share price has surged by 5.38%, which has investors questioning if this is right time to sell.Michael Rose
Stock Evaluator: Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. CRBP
$9.74
0.17
1.78%
August 6, 2026 4:00:00 PM
EST
Volume: 157,974
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Commentary & Analysis
Why Corbus Pharmaceuticals Holdings, Inc.’s (CRBP) Stock Is Up 6.05%
As of Thursday, July 23, Corbus Pharmaceuticals Holdings, Inc.’s CRBP share price has surged by 6.05%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Corbus Pharmaceuticals Holdings, Inc.’s (CRBP) Stock Is Down 5.06%
As of Monday, July 13, Corbus Pharmaceuticals Holdings, Inc.’s CRBP share price has dipped by 5.06%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Corbus Pharmaceuticals Holdings, Inc.’s (CRBP) Stock Is Up 5.33%
As of Wednesday, June 17, Corbus Pharmaceuticals Holdings, Inc.’s CRBP share price has surged by 5.33%, which has investors questioning if this is right time to sell.Michael Rose
Why Corbus Pharmaceuticals Holdings, Inc.’s (CRBP) Stock Is Up 7.59%
As of Thursday, June 04, Corbus Pharmaceuticals Holdings, Inc.’s CRBP share price has surged by 7.59%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | CRBP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $177.3 | $277.2 | 26% |
|
| Shares Out (Mil) | 18.7 | 49.2 | 30% |
|
| Institutional Ownership | 98.7% | 92.1% | 81% |
|
| Float (Mil) | 14.3 | 40.0 | 24% |
|
| Beta | 2.59 | 0.94 | 96% |
|
| Avg Daily Volume (000s) | 272 | 485 | 49% |
|
| Price Change (52-week) |
2.5% | 55.5% | 45% |
|
| Growth | CRBP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | 6.7% | (10.0%) | 50% |
|
| EPS (5yr) | 32.7% | 16.0% | 83 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (47.3%) | (15.6%) | 8% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 9 | |
| Current EPS | ($1.237) | ($4.565) | ($5.076) | |
| Month Ago EPS | ($1.237) | ($4.565) | ($5.076) | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 1 | 2 | |
| Three Months Ago EPS | ($1.244) | ($4.556) | ($4.842) | |
| Year/Year Chg | 0.7% | (22.6%) | (6.9%) | |
| Financials | CRBP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($85) | ($43) | 12% |
|
| EPS (TTM) | ($5.657) | ($1.600) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($74) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $3 | 0% |
|
| Enterprise Value (Q1) (Mil) | $16 | $162 | 10% |
|
| Valuation | CRBP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.34 | 2.58 | 34% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | CRBP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.8% | na |
|
| Net Margin | na | (70.6%) | na |
|
| ROA | (59.4%) | (53.3%) | 10% |
|
| ROE | (66.7%) | (60.8%) | 13% |
|
| Liabilities to Assets | 12.6% | 31.5% | 8% |
|
| F-Score | 2 | 3 | 7% |
|
Corbus Pharmaceuticals Holdings, Inc. did not pass any screens on 8/5/2026.
